Éric Raymond

31.5k citations
361 papers · 25.7k · 11 hit papers · h-index 74

Impact in

  • Hepatology top 0.2%
    • Hepatocellular Carcinoma Treatment and Prognosis
  • Oncology top 0.2%
    • Colorectal Cancer Treatments and Studies

Papers in

    • Cancer Treatment and Pharmacology 28
    • Colorectal Cancer Treatments and Studies 24
    • Hepatocellular Carcinoma Treatment and Prognosis 29

Éric Raymond

351 papers receiving 24.9k citations

Éric Raymond's Hit Papers

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study 2023 · 215 citations
2150+8+16Years since publication5001k1.5k2k

Peers

Éric Raymond
Comparison fields: 5 of 158
  • Hepatology 2.9k
  • Oncology 5.5k
  • Epidemiology 3.9k
  • Genetics 934
  • Pulmonary and Respiratory Medicine 2.8k
Replace Sandrine J. Faivre with:
Sandrine J. Faivre France
Ryuzo Ueda Japan
Ju Dong Yang United States
James L. Abbruzzese United States
Takuji Okusaka Japan
Jordan D. Berlin United States
Irene Oi‐Lin Ng Hong Kong
Paul B.S. Lai Hong Kong
Filippo de Braud Italy
Asif Rashid United States
Éric Raymond relative to Sandrine J. Faivre France Sandrine J. Faivre's profile →
Citations per field
00.5×2×3.1×
Sandrine J. Faivre · 1×
Citations per year

Countries citing papers authored by Éric Raymond

Since Specialization
Citations

This map shows the geographic impact of Éric Raymond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Raymond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Raymond more than expected).

Fields of papers citing papers by Éric Raymond

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éric Raymond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Raymond. The network helps show where Éric Raymond may publish in the future.

Co-authors

The 25 scholars most cited alongside Éric Raymond, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Éric Raymond Line = papers co-authored together Éric Raymond links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 361 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Hit paper breakdown →
20112044
2
EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer
Hit paper breakdown →
20121355
3
Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer
Hit paper breakdown →
20051018
4
Current development of mTOR inhibitors as anticancer agents
Hit paper breakdown →
2006838
5
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
Hit paper breakdown →
2002729
6
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Hit paper breakdown →
2013670
7
Molecular basis for sunitinib efficacy and future clinical development
Hit paper breakdown →
2007601
8 1998553
9 2005543
10
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids
Hit paper breakdown →
2015521
11
Targeting the TGFβ pathway for cancer therapy
Hit paper breakdown →
2014516
12
Oxaliplatin: mechanism of action and antineoplastic activity.
1998463
13
ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas
Hit paper breakdown →
2016459
14 2004432
15 2008416
16
Cellular and molecular pharmacology of oxaliplatin.
2002407
17 2000348
18
Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells.
1999340
19 1997325
20 2000271

About Éric Raymond

Éric Raymond is a scholar working on Oncology, Hepatology, Molecular Biology, Epidemiology and Otorhinolaryngology, having authored 361 papers that have together received 25.7k indexed citations. Recurring topics across this work include Neuroendocrine Tumor Research Advances (51 papers), Cancer therapeutics and mechanisms (43 papers), Hepatocellular Carcinoma Treatment and Prognosis (29 papers), Cancer Treatment and Pharmacology (28 papers), PI3K/AKT/mTOR signaling in cancer (26 papers), Colorectal Cancer Treatments and Studies (24 papers), Head and Neck Cancer Studies (14 papers) and Lung Cancer Treatments and Mutations (13 papers). The work is most often cited by research in Hepatology (2.9k citations), Oncology (5.5k citations), Epidemiology (3.9k citations), Genetics (934 citations) and Pulmonary and Respiratory Medicine (2.8k citations). Éric Raymond has collaborated with scholars based in France, United States and United Kingdom. Frequent co-authors include Sandrine J. Faivre, Esteban Cvitkovic, Stephen G. Chaney, Guido Kroemer, Jan Michał WOYNAROWSKI, Annemilaï Tijeras‐Raballand, Armand D.E. Gramont, Jean‐Pierre Armand, Cindy Neuzillet and Christophe Le Tourneau. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Targeted Oncology, Journal of Clinical Oncology and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact